US · AVIR · BIOTECHNOLOGY
Atea Pharmaceuticals, Inc. (AVIR) intrinsic value and stock valuation
$3.96as of 2026-11-21 · Mkt cap 420.14M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Atea Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values AVIR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AVIR’s statements →
Atea Pharmaceuticals, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2018–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Achieve Life Sciences, Inc. (ACHV) $6.78
- Allogene Therapeutics, Inc. (ALLO) $0.63
- Enanta Pharmaceuticals, Inc. (ENTA) $7.62
- Vanda Pharmaceuticals Inc. (VNDA) $3.45
- Entrada Therapeutics, Inc. (TRDA) $4.35
- Pyxis Oncology, Inc. (PYXS) $1.81
- Voyager Therapeutics, Inc. (VYGR) $1.53
- Arcturus Therapeutics Holdings Inc. (ARCT) $7.45
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $351.4M |
| Operating income | -$-180.89M | -$-192.95M | -$-164.16M | -$-130.65M | $138.4M |
| Net income | -$-158.35M | -$-168.38M | -$-135.96M | -$-115.91M | $121.2M |
| EPSd | -$-1.94M | -$-2M | -$-1.63M | -$-1.39M | $1.37M |
| Operating cash flow | -$-132.03M | -$-135.5M | -$-85.39M | -$-120.98M | -$-87M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | -$-1.94M | -$0.00 |
| Free cash flow | -$-132.03M | -$-135.5M | -$-85.39M | -$-122.92M | -$-87.01M |
| Total assets | $315.2M | $464.7M | $595M | $666.7M | $772.9M |
| Total debt | $840K | $1.64M | $2.4M | $3.12M | $200K |
| Net debt | -$-94.87M | -$-63.05M | -$-141.42M | -$-643.59M | -$-764.18M |
| Total equity | $275.4M | $438.9M | $555.2M | $640.6M | $710.1M |
| Cash and short-term investments | $301.8M | $454.7M | $578.1M | $646.7M | $764.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $351.4M |
| Cost of revenue | $0.00 | $83.4M | $70.1M | $62.4M | $167.2M |
| Gross profit | $0.00 | -$-83.37M | -$-70.09M | -$-62.39M | $184.2M |
| Research and development expenses | $148M | $145.4M | $132.8M | $88.8M | $167.2M |
| Selling, general and administrative expenses | $32.9M | $48.9M | $49.9M | $48.7M | $45.8M |
| Other expenses | $0.00 | -$-84.67M | -$-88.69M | -$-69.29M | -$-167.21M |
| Operating expenses | $180.9M | $109.6M | $94.1M | $68.3M | $45.8M |
| Cost and expenses | $180.9M | $193M | $164.2M | $130.7M | $213M |
| Interest income | $16.4M | $25.5M | $29.2M | $11.2M | $210K |
| Interest expense | $0.00 | $0.00 | $0.00 | $11.2M | $0.00 |
| Depreciation and amortization | $420K | $420K | $420K | $260K | $30K |
| Ebitda | -$-164.09M | -$-131.8M | -$-119.59M | -$-110.84M | $138.6M |
| Operating income | -$-180.89M | -$-192.95M | -$-164.16M | -$-130.65M | $138.4M |
| Total other income/expenses, net | $16.4M | $25.5M | $29.2M | $11.2M | $210K |
| Income before tax | -$-164.51M | -$-167.46M | -$-134.94M | -$-119.5M | $138.6M |
| Income tax expense | -$-6.16M | $930K | $1.02M | -$-3.59M | $17.4M |
| Net income | -$-158.35M | -$-168.38M | -$-135.96M | -$-115.91M | $121.2M |
| Weighted average shares outstanding | $81.5M | $84.3M | $83.4M | $83.3M | $82.8M |
| Weighted average diluted shares outstanding | $81.5M | $84.3M | $83.4M | $83.3M | $88.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $301.8M | $454.7M | $578.1M | $646.7M | $764.4M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $311M | $462.4M | $590.5M | $660.9M | $772.4M |
| Property, plant and equipment, net | $1.09M | $2.12M | $3.12M | $4.09M | $180K |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $200K | $300K |
| Total non-current assets | $4.23M | $2.31M | $4.51M | $5.79M | $490K |
| Total assets | $315.2M | $464.7M | $595M | $666.7M | $772.9M |
| Accounts payable | $13M | $4.46M | $4.25M | $2.55M | $4.53M |
| Short-term debt | $840K | $800K | $760K | $720K | $200K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $39.8M | $18.6M | $32.4M | $18.5M | $56.9M |
| Long-term debt | $0.00 | $840K | $1.64M | $2.4M | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $0.00 | $7.2M | $7.4M | $7.66M | $5.93M |
| Capital lease obligations | $0.00 | $1.64M | $2.4M | $3.12M | $200K |
| Total liabilities | $39.8M | $25.8M | $39.8M | $26.1M | $62.8M |
| Common stock | $80K | $80K | $80K | $80K | $80K |
| Retained earnings | -$-522.57M | -$-364.22M | -$-195.84M | -$-59.88M | $56M |
| Accumulated other comprehensive income (loss) | $170K | $230K | $210K | -$-680K | -$0.00 |
| Total equity | $275.4M | $438.9M | $555.2M | $640.6M | $710.1M |
| Total investments | $206.1M | $390M | $434.3M | $200K | $300K |
| Total debt | $840K | $1.64M | $2.4M | $3.12M | $200K |
| Net debt | -$-94.87M | -$-63.05M | -$-141.42M | -$-643.59M | -$-764.18M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-158.35M | -$-168.38M | -$-135.96M | -$-115.91M | $121.2M |
| Depreciation and amortization | $420K | $420K | $420K | $260K | $30K |
| Stock-based compensation | $20.7M | $51.8M | $49.4M | $46.7M | $39.6M |
| Change in working capital | $16.5M | -$-7.48M | $16.2M | -$-46.59M | -$-247.84M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $8.49M | $210K | $1.7M | -$-1.98M | $10.3M |
| Net cash provided by operating activities | -$-132.03M | -$-135.5M | -$-85.39M | -$-120.98M | -$-87M |
| Investments in property, plant and equipment | $0.00 | $0.00 | $0.00 | -$-1.94M | -$0.00 |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $450K | $0.00 |
| Net cash used for investing activities | $188.8M | $56.1M | $40.3M | -$-455.41M | -$0.00 |
| Common stock issued | $260K | $270K | $260K | $230K | $1.47M |
| Common stock repurchased | -$-25.52M | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-25.75M | $270K | $260K | $370K | $1.47M |
| Net change in cash | $31M | -$-79.13M | -$-44.84M | -$-576.02M | -$-85.54M |
| Cash at end of period | $95.7M | $64.7M | $143.8M | $188.7M | $764.7M |
| Operating cash flow | -$-132.03M | -$-135.5M | -$-85.39M | -$-120.98M | -$-87M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | -$-1.94M | -$0.00 |
| Free cash flow | -$-132.03M | -$-135.5M | -$-85.39M | -$-122.92M | -$-87.01M |
Line items
Line items
Line items
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
- CEO
- Jean-Pierre Sommadossi
- Employees
- 55
- Beta
- 0.27
Explore
Frequently asked questions
What is the intrinsic value of Atea Pharmaceuticals, Inc. (AVIR)?
InvestorsCraft does not currently publish an intrinsic value for AVIR. How the IC value is calculated.
Is AVIR undervalued?
InvestorsCraft does not publish an undervaluation signal for AVIR at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.